Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betaxolol is a cardioselective beta-blocker (beta-1 adrenergic antagonist) used primarily to treat hypertension and open-angle glaucoma. It works by selectively blocking beta-1 adrenergic receptors in the heart, leading to decreased heart rate, cardiac output, and blood pressure. When administered ophthalmically, it reduces intraocular pressure by decreasing aqueous humor production in the eye. Unlike non-selective beta-blockers, betaxolol has minimal effect on beta-2 receptors and thus a lower risk of bronchospasm. It does not exhibit intrinsic sympathomimetic or significant membrane-stabilizing activity. Approved uses include essential hypertension (oral), open-angle glaucoma and ocular hypertension (ophthalmic), with additional use in chronic stable angina and post-myocardial infarction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betaxolol.